BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Interleukin-32: Frenemy in cancer?

  • Han, Sora (Research Institute for Women's Health, Sookmyung Women's University) ;
  • Yang, Young (Department of Biological Sciences, Sookmyung Women's University)
  • Received : 2018.11.19
  • Published : 2019.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Interleukin-32 (IL-32) was originally identified in natural killer (NK) cells activated by IL-2 in 1992. Thus, it was named NK cell transcript 4 (NK4) because of its unknown function at that time. The function of IL-32 has been elucidated over the last decade. IL-32 is primarily considered to be a booster of inflammatory reactions because it is induced by pro-inflammatory cytokines and stimulates the production of those cytokines and vice versa. Therefore, many studies have been devoted to studying the roles of IL-32 in inflammation-associated cancers, including gastric, colon cancer, and hepatocellular carcinoma. At the same time, roles of IL-32 have also been discovered in other cancers. Collectively, IL-32 fosters the tumor progression by nuclear $factor-{\kappa}B$ ($NF-{\kappa}B$)-mediated cytokines and metalloproteinase production, as well as stimulation of differentiation into immunosuppressive cell types in some cancer types. However, it is also able to induce tumor cell apoptosis and enhance NK and cytotoxic T cell sensitivity in other cancer types. In this review, we will address the function of each IL-32 isoform in different cancer types studied to date, and suggest further strategies to comprehensively elucidate the roles of IL-32 in a context-dependent manner.

Keywords

References

  1. Zitvogel L, Tesniere A and Kroemer G (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6, 715-727 https://doi.org/10.1038/nri1936
  2. Galon J, Costes A, Sanchez-Cabo F et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964 https://doi.org/10.1126/science.1129139
  3. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA and Coffman RL (1986) Two types of murine helper T cell clone. I. definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136, 2348-2357
  4. Sakaguchi S, Miyara M, Costantino CM and Hafler DA (2010) FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 10, 490-500 https://doi.org/10.1038/nri2785
  5. O'Sullivan KE, Phelan JJ, O'Hanlon C, Lysaght J, O'Sullivan JN and Reynolds JV (2014) The role of inflammation in cancer of the esophagus. Expert Rev Gastroenterol Hepatol 8, 749-760 https://doi.org/10.1586/17474124.2014.913478
  6. Tosello-Trampont A, Surette FA, Ewald SE and Hahn YS (2017) Immunoregulatory role of NK Cells in tissue inflammation and regeneration. Front Immunol 8, 301
  7. Yadav D and Lowenfels AB (2013) The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology 144, 1252-1261 https://doi.org/10.1053/j.gastro.2013.01.068
  8. Freeman HJ (2008) Colorectal cancer risk in Crohn's disease. World J Gastroenterol 14, 1810-1811 https://doi.org/10.3748/wjg.14.1810
  9. Warren JR (2000) Gastric pathology associated with Helicobacter pylori. Gastroenterol Clin North Am 29, 705-751 https://doi.org/10.1016/S0889-8553(05)70139-4
  10. Noto JM and Peek RM Jr (2012) Helicobacter pylori: an overview. Methods Mol Biol 921, 7-10 https://doi.org/10.1007/978-1-62703-005-2_2
  11. Sakitani K, Hirata Y, Hayakawa Y et al (2012) Role of interleukin-32 in Helicobacter pylori-induced gastric inflammation. Infect Immun 80, 3795-3803 https://doi.org/10.1128/IAI.00637-12
  12. Seo EH, Kang J, Kim KH et al (2008) Detection of expressed IL-32 in human stomach cancer using ELISA and immunostaining. J Microbiol Biotechnol 18, 1606-1612
  13. Khawar MB, Abbasi MH and Sheikh N (2016) IL-32: A Novel Pluripotent inflammatory interleukin, towards gastric inflammation, gastric cancer, and chronic rhino sinusitis. Mediators Inflamm 2016, 8413768
  14. Yan H, He D, Huang X et al (2018) Role of interleukin-32 in cancer biology. Oncol Lett 16, 41-47
  15. Heinhuis B, Koenders MI, van de Loo FA, Netea MG, van den Berg WB and Joosten LA (2011) Inflammationdependent secretion and splicing of IL-$32{\gamma}$ in rheumatoid arthritis. Proc Natl Acad Sci U S A 108, 4962-4967 https://doi.org/10.1073/pnas.1016005108
  16. Heinhuis B, Plantinga TS, Semango G et al (2016) Alternatively spliced isoforms of IL-32 differentially influence cell death pathways in cancer cell lines. Carcinogenesis 37, 197-205 https://doi.org/10.1093/carcin/bgv172
  17. Sloot YJE SJ, Joosten LAB, Netea-Maier RT (2018) Insights into the role of IL-32 in cancer. Semin Immunol 38, 24-32 https://doi.org/10.1016/j.smim.2018.03.004
  18. Wang S, Chen F and Tang L (2015) IL-32 promotes breast cancer cell growth and invasiveness. Oncol Lett 9, 305-307 https://doi.org/10.3892/ol.2014.2641
  19. Taguchi A, Ohmiya N, Shirai K et al (2005) Interleukin-8 promoter polymorphism increases the risk of atrophic gastritis and gastric cancer in Japan. Cancer Epidemiol Biomarkers Prev 14, 2487-2493 https://doi.org/10.1158/1055-9965.EPI-05-0326
  20. Wang YM, Li ZX, Tang FB et al (2016) Association of genetic polymorphisms of interleukins with gastric cancer and precancerous gastric lesions in a high-risk Chinese population. Tumour Biol 37, 2233-2242 https://doi.org/10.1007/s13277-015-4022-x
  21. Tsai CY, Wang CS, Tsai MM et al (2014) Interleukin-32 increases human gastric cancer cell invasion associated with tumor progression and metastasis. Clin Cancer Res 20, 2276-2288 https://doi.org/10.1158/1078-0432.CCR-13-1221
  22. Ishigami S, Arigami T, Uchikado Y et al (2013) IL-32 expression is an independent prognostic marker for gastric cancer. Med Oncol 30, 472 https://doi.org/10.1007/s12032-013-0472-4
  23. Erturk K, Tastekin D, Serilmez M, Bilgin E, Bozbey HU and Vatansever S (2006) Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer. Tumour Biol 37, 405-412
  24. Chang WJ, Du Y, Zhao X, Ma LY and Cao GW (2014) Inflammation-related factors predicting prognosis of gastric cancer. World J Gastroenterol 20, 4586-4596 https://doi.org/10.3748/wjg.v20.i16.4586
  25. Nishida A, Andoh A, Inatomi O and Fujiyama Y (2009) Interleukin-32 expression in the pancreas. J Biol Chem 284, 17868-17876 https://doi.org/10.1074/jbc.M900368200
  26. van Hogezand RA, Eichhorn RF, Choudry A, Veenendaal RA and Lamers CB (2002) Malignancies in inflammatory bowel disease: fact or fiction? Scand J Gastroenterol Suppl, 48-53
  27. Yun HM, Park KR, Kim EC, Han SB, Yoon DY and Hong JT (2015) IL-32alpha suppresses colorectal cancer development via TNFR1-mediated death signaling. Oncotarget 6, 9061-9072 https://doi.org/10.18632/oncotarget.3197
  28. Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S and Mori H (2003) A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci 94, 965-973 https://doi.org/10.1111/j.1349-7006.2003.tb01386.x
  29. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y and Nakaya R (1990) A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98, 694-702 https://doi.org/10.1016/0016-5085(90)90290-H
  30. Yang Y, Wang Z, Zhou Y, Wang X, Xiang J and Chen Z (2015) Dysregulation of over-expressed IL-32 in colorectal cancer induces metastasis. World J Surg Oncol 13, 146 https://doi.org/10.1186/s12957-015-0552-3
  31. Khawar MB, Mukhtar M, Abbasi MH, Sheikh N (2017) IL-$32{\theta}$: a recently identified anti-inflammatory variant of IL-32 and its preventive role in various disorders and tumor suppressor activity. Am J Transl Res 9, 4726-4737
  32. Catalan V, Gomez-Ambrosi J, Rodriguez A et al (2017) IL-$32{\alpha}$-induced inflammation constitutes a link between obesity and colon cancer. Oncoimmunology 6, e1328338
  33. Sherman M and Klein A (2004) AASLD single-topic research conference on hepatocellular carcinoma: Conference proceedings. Hepatology 40, 1465-1473 https://doi.org/10.1002/hep.20528
  34. Xu H, Zhang S, Pan X et al (2016) TIMP-1 expression induced by IL-32 is mediated through activation of AP-1 signal pathway. Int Immunopharmacol 38, 233-237 https://doi.org/10.1016/j.intimp.2016.06.002
  35. Kim SH, Han SY, Azam T, Yoon DY and Dinarello CA (2005) Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 22, 131-142 https://doi.org/10.1016/S1074-7613(04)00380-2
  36. Kudo M, Ogawa E, Kinose D et al (2012) Oxidative stress induced interleukin-32 mRNA expression in human bronchial epithelial cells. Respir Res 13, 19 https://doi.org/10.1186/1465-9921-13-19
  37. Dinarello CA and Kim SH (2006) IL-32, a novel cytokine with a possible role in disease. Ann Rheum Dis 65 Suppl 3, iii61-64
  38. Pan X, Cao H, Lu J et al (2011) Interleukin-32 expression induced by hepatitis B virus protein X is mediated through activation of NF-kappaB. Mol Immunol 48, 1573-1577 https://doi.org/10.1016/j.molimm.2011.03.012
  39. Moschen AR, Fritz T, Clouston AD et al (2011) Interleukin-32: a new proinflammatory cytokine involved in hepatitis C virus-related liver inflammation and fibrosis. Hepatology 53, 1819-1829 https://doi.org/10.1002/hep.24285
  40. Kang YH, Park MY, Yoon DY et al (2012) Dysregulation of overexpressed IL-32alpha in hepatocellular carcinoma suppresses cell growth and induces apoptosis through inactivation of NF-kappaB and Bcl-2. Cancer Lett 318, 226-233 https://doi.org/10.1016/j.canlet.2011.12.023
  41. Zhao WB, Wang QL, Xu YT, Xu SF, Qiu Y, Zhu F (2018) Overexpression of interleukin-$32{\alpha}$ promotes invasion by modulating VEGF in hepatocellular carcinoma. Oncol Rep. 39, 1155-1162
  42. Iliaz R, Akyuz U, Tekin D et al (2016) Role of several cytokines and adhesion molecules in the diagnosis and prediction of survival of hepatocellular carcinoma. Arab J Gastroenterol 17, 164-167 https://doi.org/10.1016/j.ajg.2016.10.002
  43. Kim DH, Park ES, Lee AR et al (2018) Intracellular interleukin-32gamma mediates antiviral activity of cytokines against hepatitis B virus. Nat Commun 9, 3284 https://doi.org/10.1038/s41467-018-05782-5
  44. Sato M, Shames DS, Gazdar AF and Minna JD (2007) A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2, 327-343 https://doi.org/10.1097/01.JTO.0000263718.69320.4c
  45. Zeng Q, Li S, Zhou Y et al (2013) Interleukin-32 contributes to invasion and metastasis of primary lung adenocarcinoma via NF-kappaB induced matrix metalloproteinases 2 and 9 expression. Cytokine 65, 24-32 https://doi.org/10.1016/j.cyto.2013.09.017
  46. Sorrentino C and Di Carlo E (2009) Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. Am J Respir Crit Care Med 180, 769-779 https://doi.org/10.1164/rccm.200903-0400OC
  47. Wang Y, Yang Y, Zhu Y, Li L, Chen F and Zhang L (2017) Polymorphisms and expression of IL-32: impact on genetic susceptibility and clinical outcome of lung cancer. Biomarkers 22, 165-170 https://doi.org/10.1080/1354750X.2016.1252956
  48. Yun J, Park MH, Son DJ et al (2018) IL-32 gamma reduces lung tumor development through upregulation of TIMP-3 overexpression and hypomethylation. Cell Death Dis 9, 306 https://doi.org/10.1038/s41419-018-0375-6
  49. Park JS, Choi SY, Lee JH et al (2013) Interleukin-32beta stimulates migration of MDA-MB-231 and MCF-7cells via the VEGF-STAT3 signaling pathway. Cell Oncol (Dordr) 36, 493-503 https://doi.org/10.1007/s13402-013-0154-4
  50. Park JS, Lee S, Jeong AL et al (2014) Hypoxia-induced IL-32beta increases glycolysis in breast cancer cells. Cancer Lett 356, 800-808 https://doi.org/10.1016/j.canlet.2014.10.030
  51. Ainscough JS, Frank Gerberick G, Zahedi-Nejad M et al (2014) Dendritic cell IL-1alpha and IL-1beta are polyubiquitinated and degraded by the proteasome. J Biol Chem 289, 35582-35592 https://doi.org/10.1074/jbc.M114.595686
  52. Yong HJ, Park JS, Lee Jeong A et al (2017) Von Hippel-Lindau regulates interleukin-32beta stability in ovarian cancer cells. Oncotarget 8, 69833-69846 https://doi.org/10.18632/oncotarget.19311
  53. Ternette N, Olde Nordkamp MJM, Muller J et al (2018) Immunopeptidomic profiling of HLA-A2-positive triple negative breast cancer identifies potential immunotherapy target antigens. Proteomics 18, e1700465 https://doi.org/10.1002/pmic.201700465
  54. Lee S, Kim JH, Kim H et al (2010) Activation of the interleukin-32 pro-inflammatory pathway in response to human papillomavirus infection and over-expression of interleukin-32 controls the expression of the human papillomavirus oncogene. Immunology 132, 410-420 https://doi.org/10.1111/j.1365-2567.2010.03377.x
  55. Lee S, Kim H, Kang JW et al (2011) The biflavonoid amentoflavone induces apoptosis via suppressing E7 expression, cell cycle arrest at sub-G(1) phase, and mitochondria-emanated intrinsic pathways in human cervical cancer cells. J Med Food 14, 808-816 https://doi.org/10.1089/jmf.2010.1428
  56. Goda C, Kanaji T, Kanaji S et al (2006) Involvement of IL-32 in activation-induced cell death in T cells. Int Immunol 18, 233-240 https://doi.org/10.1093/intimm/dxh339
  57. Zhang F, Suarez G, Sha J, Sierra JC, Peterson JW and Chopra AK (2009) Phospholipase A2-activating protein (PLAA) enhances cisplatin-induced apoptosis in HeLa cells. Cell Signal 21, 1085-1099 https://doi.org/10.1016/j.cellsig.2009.02.018
  58. Cui Y, Sun Z, Li X et al (2016) Expression and clinical significance of cyclooxygenase-2 and interleukin-32 in primary gastric B-cell lymphoma. Oncol Lett 11, 693-698 https://doi.org/10.3892/ol.2015.3950
  59. Yamac D, Ayyildiz T, Coskun U et al (2008) Cyclooxygenase-2 expression and its association with angiogenesis, Helicobacter pylori, and clinicopathologic characteristics of gastric carcinoma. Pathol Res Pract 204, 527-536 https://doi.org/10.1016/j.prp.2008.01.002
  60. Konturek PC, Hartwich A, Zuchowicz M et al (2000) Helicobacter pylori, gastrin and cyclooxygenases in gastric cancer. J Physiol Pharmacol 51, 737-749
  61. Lee S, Kim JH, Kim H et al (2011) Activation of the interleukin-32 pro-inflammatory pathway in response to human papillomavirus infection and over-expression of interleukin-32 controls the expression of the human papillomavirus oncogene. Immunology 132, 410-420 https://doi.org/10.1111/j.1365-2567.2010.03377.x
  62. van Kester MS, Borg MK, Zoutman WH et al (2012) A meta-analysis of gene expression data identifies a molecular signature characteristic for tumor-stage mycosis fungoides. J Invest Dermatol 132, 2050-2059 https://doi.org/10.1038/jid.2012.117
  63. Suga H, Sugaya M, Miyagaki T et al (2013) The role of IL-32 in cutaneous T-cell lymphoma. J Invest Dermatol 134, 1428-1435 https://doi.org/10.1038/jid.2013.488
  64. Cheon S, Lee JH, Park S et al (2011) Overexpression of IL-32alpha increases natural killer cell-mediated killing through up-regulation of Fas and UL16-binding protein 2 (ULBP2) expression in human chronic myeloid leukemia cells. J Biol Chem 286, 12049-12055 https://doi.org/10.1074/jbc.M110.159756
  65. Raulet DH (2003) Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3, 781-790 https://doi.org/10.1038/nri1199
  66. Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR and Raulet DH (2002) The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17, 19-29 https://doi.org/10.1016/S1074-7613(02)00333-3
  67. Park MH, Song MJ, Cho MC et al (2011) Interleukin-32 enhances cytotoxic effect of natural killer cells to cancer cells via activation of death receptor 3. Immunology 135, 63-72 https://doi.org/10.1111/j.1365-2567.2011.03513.x
  68. Smyth MJ, Cretney E, Takeda K et al (2001) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 193, 661-670 https://doi.org/10.1084/jem.193.6.661
  69. Screpanti V, Wallin RP, Grandien A and Ljunggren HG (2005) Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells. Mol Immunol 42, 495-499 https://doi.org/10.1016/j.molimm.2004.07.033
  70. Yun HM, Oh JH, Shim JH et al (2013) Antitumor activity of IL-32beta through the activation of lymphocytes, and the inactivation of NF-kappaB and STAT3 signals. Cell Death Dis 4, e640 https://doi.org/10.1038/cddis.2013.166
  71. Oh JH, Cho MC, Kim JH et al (2011) IL-32gamma inhibits cancer cell growth through inactivation of NF-kappaB and STAT3 signals. Oncogene 30, 3345-3359 https://doi.org/10.1038/onc.2011.52
  72. Qu Y, Taylor JL, Bose A and Storkus WJ (2011) Therapeutic effectiveness of intratumorally delivered dendritic cells engineered to express the pro-inflammatory cytokine, interleukin (IL)-32. Cancer Gene Ther 18, 663-673 https://doi.org/10.1038/cgt.2011.37
  73. Ohmatsu H, Humme D, Gonzalez J et al (2017) IL-32 induces indoleamine 2,3-dioxygenase+CD1c+ dendritic cells and indoleamine 2,3-dioxygenase+CD163+ macrophages: Relevance to mycosis fungoides progression. Oncoimmunology 6, e1181237 https://doi.org/10.1080/2162402X.2016.1181237
  74. Chang CJ, Chien Y, Lu KH et al (2011) Oct4-related cytokine effects regulate tumorigenic properties of colorectal cancer cells. Biochem Biophys Res Commun 415, 245-251 https://doi.org/10.1016/j.bbrc.2011.10.024
  75. Moldenhauer A, Futschik M, Lu H et al (2011) Interleukin 32 promotes hematopoietic progenitor expansion and attenuates bone marrow cytotoxicity. Eur J Immunol 41, 1774-1786 https://doi.org/10.1002/eji.201040986